Abstract OT1-01-05: Endocrine treatment alone as primary treatment for elderly patients with estrogen receptor positive good prognosis operable breast cancer: A single arm phase II, single institution study

P3-14-27: Pegylated Liposomal Doxorubicin (PLD) as Primary Treatment in Estrogen Receptor (ER) and HER2 Poor Breast Cancer and Risk of Developing Cardiotoxicity or Elderly Patients (pt). Results from the Phase II CAPRICE Study.

10.1158/0008-5472.sabcs11-p3-14-27 ◽

2011 ◽

Author(s):

MJ Gil ◽

C Bellet ◽

A Llombart ◽

B Ojeda ◽

L Manso ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Elderly Patients ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Pegylated Liposomal Doxorubicin ◽

Primary Treatment

Abstract OT2-01-01: Endocrine therapy alone as primary treatment for elderly patients with clinical stage I to III estrogen receptor positive breast cancer with low recurrence score

10.1158/1538-7445.sabcs15-ot2-01-01 ◽

2016 ◽

Author(s):

R Aft ◽

K Trinkaus ◽

C Ma

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Elderly Patients ◽

Endocrine Therapy ◽

Clinical Stage ◽

Recurrence Score ◽

Primary Treatment ◽

Stage I ◽

Positive Breast Cancer

Faculty Opinions recommendation of Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.734565867.793581155 ◽

2020 ◽

Author(s):

David Potter

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Neoadjuvant Therapy ◽

Early Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Randomized Phase Ii ◽

Estrogen receptor positive operable breast cancer: Does menopausal status impact on HER2 and progesterone receptor status?

The Breast ◽

10.1016/j.breast.2011.05.009 ◽

2011 ◽

Vol 20 (6) ◽

pp. 519-524 ◽

Cited By ~ 3

Author(s):

Ning Wang ◽

Bin Wang ◽

Yajie Wang ◽

Jia Hu

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Progesterone Receptor ◽

Menopausal Status ◽

Operable Breast Cancer ◽

Progesterone Receptor Status ◽

Receptor Status ◽

Clinical pattern of primary systemic therapy and outcomes of estrogen receptor-positive, HER2-negative metastatic breast cancer: a review of a single institution

Breast Cancer Research and Treatment ◽

10.1007/s10549-017-4478-z ◽

2017 ◽

Vol 166 (3) ◽

pp. 911-917 ◽

Cited By ~ 2

Author(s):

Junichiro Watanabe ◽

T. Hayashi ◽

Y. Tadokoro ◽

S. Nishimura ◽

K. Takahashi

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Metastatic Breast Cancer ◽

Systemic Therapy ◽

Metastatic Breast ◽

Single Institution ◽

Primary Systemic Therapy ◽

Clinical Pattern ◽

Improved Estrogen Receptor Assessment by PET Using the Novel Radiotracer 18F-4FMFES in Estrogen Receptor–Positive Breast Cancer Patients: An Ongoing Phase II Clinical Trial

Journal of Nuclear Medicine ◽

10.2967/jnumed.117.194654 ◽

2017 ◽

Vol 59 (2) ◽

pp. 197-203 ◽

Cited By ~ 12

Author(s):

Michel Paquette ◽

Éric Lavallée ◽

Serge Phoenix ◽

René Ouellet ◽

Helena Senta ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Estrogen Receptor ◽

Cancer Patients ◽

Phase Ii ◽

The Novel ◽

Breast Cancer Patients ◽

Ongoing Phase ◽

Positive Breast Cancer

Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study

Cancer Medicine ◽

10.1002/cam4.2423 ◽

2019 ◽

Vol 8 (12) ◽

pp. 5468-5481

Author(s):

Nobuaki Sato ◽

Norikazu Masuda ◽

Takashi Morimoto ◽

Takayuki Ueno ◽

Chizuko Kanbayashi ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Phase Ii ◽

Phase Ii Study ◽

Open Label ◽

Open Label Phase ◽

Positive Breast Cancer

Randomised Phase Ii Study Evaluating, As First-Line Chemotherapy, Weekly Oral Vinorelbine As a Single-Agent Versus Weekly Paclitaxel As a Single-Agent in Estrogen Receptor Positive, Her2-Negative Patients with Advanced Breast Cancer (Norbreast-231 Trial)

Annals of Oncology ◽

10.1093/annonc/mdu329.63 ◽

2014 ◽

Vol 25 ◽

pp. iv136

Author(s):

M. Aapro ◽

E. Staroslawska ◽

S. Morales ◽

M. Ruiz Borrego ◽

S. Cinieri ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Single Agent ◽

First Line ◽

Oral Vinorelbine ◽

Line Chemotherapy

A Phase II Study (FINDER 2) Comparing Three Dosing Regimens of Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Advanced Breast Cancer.

10.1158/0008-5472.sabcs-09-4095 ◽

2009 ◽

Author(s):

K. Pritchard ◽

J. Rolski ◽

Z. Pápai ◽

L. Mauriac ◽

F. Cardoso ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Phase Ii ◽

Phase Ii Study ◽

Advanced Breast ◽

Dosing Regimens

Abstract P3-10-11: Clinical Significance of Progesterone Receptor and HER2 Status in Estrogen Receptor-Positive, Operable Breast Cancer with Adjuvant Tamoxifen: Consistent Prognostic Impact of HER2 Status Over Time

10.1158/0008-5472.sabcs10-p3-10-11 ◽

2010 ◽

Author(s):

YW Moon ◽

S Park ◽

JH Sohn ◽

DR Kang ◽

JS Koo ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Progesterone Receptor ◽

Clinical Significance ◽

Operable Breast Cancer ◽

Adjuvant Tamoxifen ◽

Her2 Status ◽

Prognostic Impact ◽

Over Time